Iraqi Journal of Hematology

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 7  |  Issue : 1  |  Page : 1--7

Evaluation of chronic myeloid leukemia patients and their molecular responses to tyrosine kinase inhibitors in Erbil city, Iraq


Kawa Muhamedamin Hasan 
 Department of Medicine, Hawler Medical University, College of Medicine, Nanakaly Hospital for Blood Diseases and Oncology, Erbil, Iraq

Correspondence Address:
Dr. Kawa Muhamedamin Hasan
Hawler Medical University, Nanakaly Hospital for Blood Diseases and Oncology, Erbil
Iraq

Background: Chronic myeloid leukemia (CML) is one of the indolent myeloproliferative neoplasms. It is characterized by the presence of the Philadelphia chromosome, a translocation between chromosomes 9 and 22 or BCR-ABL1 gene. Objectives: The aims of this study were to evaluate characteristics of CML patients and their molecular response to tyrosine kinase inhibitors (TKI) in Erbil city in Iraq. Patients and Methods: Seventy-six patients with CML were recruited in this retrospective and prospective study from February 2014 to March 2016, at Nanakaly Hospital for Blood Diseases in Erbil city – Kurdistan region of Iraq. They were evaluated from clinical point of view and their laboratory data, and molecular responses to TKI based on polymerase chain reaction were analyzed. Results: The median age of participants was 45 years; the male: female ratio was 1:0.9. The main presenting features were abdominal fullness in 66% and splenomegaly in 95% of patients. Nearly 66% of them had low European Treatment and Outcome Study (EUTOS) score; 70% of patient had major or complete molecular responses (MMR/CMR). There was a significant difference between patients who did versus who did not achieve MMR/CMR in hemoglobin level, promyelocyte, and myelocyte percent, EUTOS, and Sokal scores (P = 0.02, 0.006, 0.03, 0.001, and 0.02, respectively). Conclusion: In the current study, CML patients were at a younger age of onset, and more high EUTOS score. The majority of patients achieved MMR with frontline Imatinib or Nilotinib and those who switched from Imatinib to Nilotinib as well.


How to cite this article:
Hasan KM. Evaluation of chronic myeloid leukemia patients and their molecular responses to tyrosine kinase inhibitors in Erbil city, Iraq.Iraqi J Hematol 2018;7:1-7


How to cite this URL:
Hasan KM. Evaluation of chronic myeloid leukemia patients and their molecular responses to tyrosine kinase inhibitors in Erbil city, Iraq. Iraqi J Hematol [serial online] 2018 [cited 2022 Jan 16 ];7:1-7
Available from: https://www.ijhonline.org/article.asp?issn=2072-8069;year=2018;volume=7;issue=1;spage=1;epage=7;aulast=Hasan;type=0